Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study
We have previously characterised functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's disease. To gain further knowledge on the preclinical phase of Alzheimer's disease, we sought to characterise structural and functional MRI, CSF, and plasma biomarkers...
Saved in:
| Published in | Lancet neurology Vol. 11; no. 12; pp. 1048 - 1056 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Elsevier Ltd
01.12.2012
Elsevier Limited |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | We have previously characterised functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's disease. To gain further knowledge on the preclinical phase of Alzheimer's disease, we sought to characterise structural and functional MRI, CSF, and plasma biomarkers in a cohort of young adults carrying a high-penetrance autosomal dominant mutation that causes early-onset Alzheimer's disease.
Between January and August, 2010, 18–26-year-old presenilin 1 (PSEN1) E280A mutation carriers and non-carriers from the Colombian Alzheimer's Prevention Initiative Registry in Medellín Antioquia, Colombia, had structural MRI, functional MRI during associative memory encoding and novel viewing and control tasks, and cognitive assessments. Consenting participants also had lumbar punctures and venepunctures. Outcome measures were task-dependent hippocampal or parahippocampal activations and precuneus or posterior cingulate deactivations, regional grey matter reductions, CSF Aβ1–42, total tau and phospho-tau181 concentrations, and plasma Aβ1–42 concentrations and Aβ1–42:Aβ1–40 ratios. Structural and functional MRI data were compared using automated brain mapping algorithms and search regions related to Alzheimer's disease. Cognitive and fluid biomarkers were compared using Mann-Whitney tests.
44 participants were included: 20 PSEN1 E280A mutation carriers and 24 non-carriers. The carrier and non-carrier groups did not differ significantly in their dementia ratings, neuropsychological test scores, or proportion of apolipoprotein E (APOE) ɛ4 carriers. Compared with non-carriers, carriers had greater right hippocampal and parahippocampal activation (p=0·001 and p<0·014, respectively, after correction for multiple comparisons), less precuneus and posterior cingulate deactivation (all p<0·010 after correction), and less grey matter in several parietal regions (all p<0·002 uncorrected and corrected p=0·009 in the right parietal search region). In the 20 participants (ten PSEN1 E280A mutation carriers and ten non-carriers) who had lumbar punctures and venepunctures, mutation carriers had higher CSF Aβ1–42 concentrations (p=0·008) and plasma Aβ1–42 concentrations (p=0·01) than non-carriers.
Young adults at genetic risk for autosomal dominant Alzheimer's disease have functional and structural MRI findings and CSF and plasma biomarker findings consistent with Aβ1–42 overproduction. Although the extent to which the underlying brain changes are either neurodegenerative or developmental remain to be determined, this study shows the earliest known biomarker changes in cognitively normal people at genetic risk for autosomal dominant Alzheimer's disease.
Banner Alzheimer's Foundation, Nomis Foundation, Anonymous Foundation, Forget Me Not Initiative, Boston University Department of Psychology, Colciencias, National Institute on Aging, National Institute of Neurological Disorders and Stroke, and the State of Arizona. |
|---|---|
| AbstractList | We have previously characterised functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's disease. To gain further knowledge on the preclinical phase of Alzheimer's disease, we sought to characterise structural and functional MRI, CSF, and plasma biomarkers in a cohort of young adults carrying a high-penetrance autosomal dominant mutation that causes early-onset Alzheimer's disease.
Between January and August, 2010, 18–26-year-old presenilin 1 (PSEN1) E280A mutation carriers and non-carriers from the Colombian Alzheimer's Prevention Initiative Registry in Medellín Antioquia, Colombia, had structural MRI, functional MRI during associative memory encoding and novel viewing and control tasks, and cognitive assessments. Consenting participants also had lumbar punctures and venepunctures. Outcome measures were task-dependent hippocampal or parahippocampal activations and precuneus or posterior cingulate deactivations, regional grey matter reductions, CSF Aβ1–42, total tau and phospho-tau181 concentrations, and plasma Aβ1–42 concentrations and Aβ1–42:Aβ1–40 ratios. Structural and functional MRI data were compared using automated brain mapping algorithms and search regions related to Alzheimer's disease. Cognitive and fluid biomarkers were compared using Mann-Whitney tests.
44 participants were included: 20 PSEN1 E280A mutation carriers and 24 non-carriers. The carrier and non-carrier groups did not differ significantly in their dementia ratings, neuropsychological test scores, or proportion of apolipoprotein E (APOE) ɛ4 carriers. Compared with non-carriers, carriers had greater right hippocampal and parahippocampal activation (p=0·001 and p<0·014, respectively, after correction for multiple comparisons), less precuneus and posterior cingulate deactivation (all p<0·010 after correction), and less grey matter in several parietal regions (all p<0·002 uncorrected and corrected p=0·009 in the right parietal search region). In the 20 participants (ten PSEN1 E280A mutation carriers and ten non-carriers) who had lumbar punctures and venepunctures, mutation carriers had higher CSF Aβ1–42 concentrations (p=0·008) and plasma Aβ1–42 concentrations (p=0·01) than non-carriers.
Young adults at genetic risk for autosomal dominant Alzheimer's disease have functional and structural MRI findings and CSF and plasma biomarker findings consistent with Aβ1–42 overproduction. Although the extent to which the underlying brain changes are either neurodegenerative or developmental remain to be determined, this study shows the earliest known biomarker changes in cognitively normal people at genetic risk for autosomal dominant Alzheimer's disease.
Banner Alzheimer's Foundation, Nomis Foundation, Anonymous Foundation, Forget Me Not Initiative, Boston University Department of Psychology, Colciencias, National Institute on Aging, National Institute of Neurological Disorders and Stroke, and the State of Arizona. We have previously characterised functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's disease. To gain further knowledge on the preclinical phase of Alzheimer's disease, we sought to characterise structural and functional MRI, CSF, and plasma biomarkers in a cohort of young adults carrying a high-penetrance autosomal dominant mutation that causes early-onset Alzheimer's disease. Between January and August, 2010, 18-26-year-old presenilin 1 (PSEN1) E280A mutation carriers and non-carriers from the Colombian Alzheimer's Prevention Initiative Registry in Medellín Antioquia, Colombia, had structural MRI, functional MRI during associative memory encoding and novel viewing and control tasks, and cognitive assessments. Consenting participants also had lumbar punctures and venepunctures. Outcome measures were task-dependent hippocampal or parahippocampal activations and precuneus or posterior cingulate deactivations, regional grey matter reductions, CSF Aβ1-42, total tau and phospho-tau181 concentrations, and plasma Aβ1-42 concentrations and Aβ1-42_Aβ1-40 ratios. Structural and functional MRI data were compared using automated brain mapping algorithms and search regions related to Alzheimer's disease. Cognitive and fluid biomarkers were compared using Mann-Whitney tests. 44 participants were included: 20 PSEN1 E280A mutation carriers and 24 non-carriers. The carrier and non-carrier groups did not differ significantly in their dementia ratings, neuropsychological test scores, or proportion of apolipoprotein E (APOE) [varepsilon]4 carriers. Compared with non-carriers, carriers had greater right hippocampal and parahippocampal activation (p=0·001 and p<0·014, respectively, after correction for multiple comparisons), less precuneus and posterior cingulate deactivation (all p<0·010 after correction), and less grey matter in several parietal regions (all p<0·002 uncorrected and corrected p=0·009 in the right parietal search region). In the 20 participants (ten PSEN1 E280A mutation carriers and ten non-carriers) who had lumbar punctures and venepunctures, mutation carriers had higher CSF Aβ1-42 concentrations (p=0·008) and plasma Aβ1-42 concentrations (p=0·01) than non-carriers. Young adults at genetic risk for autosomal dominant Alzheimer's disease have functional and structural MRI findings and CSF and plasma biomarker findings consistent with Aβ1-42 overproduction. Although the extent to which the underlying brain changes are either neurodegenerative or developmental remain to be determined, this study shows the earliest known biomarker changes in cognitively normal people at genetic risk for autosomal dominant Alzheimer's disease. Banner Alzheimer's Foundation, Nomis Foundation, Anonymous Foundation, Forget Me Not Initiative, Boston University Department of Psychology, Colciencias, National Institute on Aging, National Institute of Neurological Disorders and Stroke, and the State of Arizona. We have previously characterised functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's disease. To gain further knowledge on the preclinical phase of Alzheimer's disease, we sought to characterise structural and functional MRI, CSF, and plasma biomarkers in a cohort of young adults carrying a high-penetrance autosomal dominant mutation that causes early-onset Alzheimer's disease. Methods: Between January and August, 2010, 18a26-year-old presenilin 1 (PSEN1) E280A mutation carriers and non-carriers from the Colombian Alzheimer's Prevention Initiative Registry in Medellin Antioquia, Colombia, had structural MRI, functional MRI during associative memory encoding and novel viewing and control tasks, and cognitive assessments. Consenting participants also had lumbar punctures and venepunctures. Outcome measures were task-dependent hippocampal or parahippocampal activations and precuneus or posterior cingulate deactivations, regional grey matter reductions, CSF A[beta]1a42, total tau and phospho-tau181 concentrations, and plasma A[beta]1a42 concentrations and A[beta]1a42: A[beta]1a40 ratios. Structural and functional MRI data were compared using automated brain mapping algorithms and search regions related to Alzheimer's disease. Cognitive and fluid biomarkers were compared using Mann-Whitney tests. Findings: 44 participants were included: 20 PSEN1 E280A mutation carriers and 24 non-carriers. The carrier and non-carrier groups did not differ significantly in their dementia ratings, neuropsychological test scores, or proportion of apolipoprotein E (APOE) [epsilon]4 carriers. Compared with non-carriers, carriers had greater right hippocampal and parahippocampal activation (p=0ADT001 and p<0ADT014, respectively, after correction for multiple comparisons), less precuneus and posterior cingulate deactivation (all p<0ADT010 after correction), and less grey matter in several parietal regions (all p<0ADT002 uncorrected and corrected p=0ADT009 in the right parietal search region). In the 20 participants (ten PSEN1 E280A mutation carriers and ten non-carriers) who had lumbar punctures and venepunctures, mutation carriers had higher CSF A[beta]1a42 concentrations (p=0ADT008) and plasma A[beta]1a42 concentrations (p=0ADT01) than non-carriers. Interpretation: Young adults at genetic risk for autosomal dominant Alzheimer's disease have functional and structural MRI findings and CSF and plasma biomarker findings consistent with A[beta]1a42 overproduction. Although the extent to which the underlying brain changes are either neurodegenerative or developmental remain to be determined, this study shows the earliest known biomarker changes in cognitively normal people at genetic risk for autosomal dominant Alzheimer's disease. Funding: Banner Alzheimer's Foundation, Nomis Foundation, Anonymous Foundation, Forget Me Not Initiative, Boston University Department of Psychology, Colciencias, National Institute on Aging, National Institute of Neurological Disorders and Stroke, and the State of Arizona. Summary Background We have previously characterised functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's disease. To gain further knowledge on the preclinical phase of Alzheimer's disease, we sought to characterise structural and functional MRI, CSF, and plasma biomarkers in a cohort of young adults carrying a high-penetrance autosomal dominant mutation that causes early-onset Alzheimer's disease. Methods Between January and August, 2010, 18–26-year-old presenilin 1 (PSEN1) E280A mutation carriers and non-carriers from the Colombian Alzheimer's Prevention Initiative Registry in Medellín Antioquia, Colombia, had structural MRI, functional MRI during associative memory encoding and novel viewing and control tasks, and cognitive assessments. Consenting participants also had lumbar punctures and venepunctures. Outcome measures were task-dependent hippocampal or parahippocampal activations and precuneus or posterior cingulate deactivations, regional grey matter reductions, CSF Aβ1–42 , total tau and phospho-tau181 concentrations, and plasma Aβ1–42 concentrations and Aβ1–42 :Aβ1–40 ratios. Structural and functional MRI data were compared using automated brain mapping algorithms and search regions related to Alzheimer's disease. Cognitive and fluid biomarkers were compared using Mann-Whitney tests. Findings 44 participants were included: 20 PSEN1 E280A mutation carriers and 24 non-carriers. The carrier and non-carrier groups did not differ significantly in their dementia ratings, neuropsychological test scores, or proportion of apolipoprotein E (APOE) ε4 carriers. Compared with non-carriers, carriers had greater right hippocampal and parahippocampal activation (p=0·001 and p<0·014, respectively, after correction for multiple comparisons), less precuneus and posterior cingulate deactivation (all p<0·010 after correction), and less grey matter in several parietal regions (all p<0·002 uncorrected and corrected p=0·009 in the right parietal search region). In the 20 participants (ten PSEN1 E280A mutation carriers and ten non-carriers) who had lumbar punctures and venepunctures, mutation carriers had higher CSF Aβ1–42 concentrations (p=0·008) and plasma Aβ1–42 concentrations (p=0·01) than non-carriers. Interpretation Young adults at genetic risk for autosomal dominant Alzheimer's disease have functional and structural MRI findings and CSF and plasma biomarker findings consistent with Aβ1–42 overproduction. Although the extent to which the underlying brain changes are either neurodegenerative or developmental remain to be determined, this study shows the earliest known biomarker changes in cognitively normal people at genetic risk for autosomal dominant Alzheimer's disease. Funding Banner Alzheimer's Foundation, Nomis Foundation, Anonymous Foundation, Forget Me Not Initiative, Boston University Department of Psychology, Colciencias, National Institute on Aging, National Institute of Neurological Disorders and Stroke, and the State of Arizona. We have previously characterised functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's disease. To gain further knowledge on the preclinical phase of Alzheimer's disease, we sought to characterise structural and functional MRI, CSF, and plasma biomarkers in a cohort of young adults carrying a high-penetrance autosomal dominant mutation that causes early-onset Alzheimer's disease.BACKGROUNDWe have previously characterised functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's disease. To gain further knowledge on the preclinical phase of Alzheimer's disease, we sought to characterise structural and functional MRI, CSF, and plasma biomarkers in a cohort of young adults carrying a high-penetrance autosomal dominant mutation that causes early-onset Alzheimer's disease.Between January and August, 2010, 18-26-year-old presenilin 1 (PSEN1) E280A mutation carriers and non-carriers from the Colombian Alzheimer's Prevention Initiative Registry in Medellín Antioquia, Colombia, had structural MRI, functional MRI during associative memory encoding and novel viewing and control tasks, and cognitive assessments. Consenting participants also had lumbar punctures and venepunctures. Outcome measures were task-dependent hippocampal or parahippocampal activations and precuneus or posterior cingulate deactivations, regional grey matter reductions, CSF Aβ(1-42), total tau and phospho-tau(181) concentrations, and plasma Aβ(1-42) concentrations and Aβ(1-42):Aβ(1-40) ratios. Structural and functional MRI data were compared using automated brain mapping algorithms and search regions related to Alzheimer's disease. Cognitive and fluid biomarkers were compared using Mann-Whitney tests.METHODSBetween January and August, 2010, 18-26-year-old presenilin 1 (PSEN1) E280A mutation carriers and non-carriers from the Colombian Alzheimer's Prevention Initiative Registry in Medellín Antioquia, Colombia, had structural MRI, functional MRI during associative memory encoding and novel viewing and control tasks, and cognitive assessments. Consenting participants also had lumbar punctures and venepunctures. Outcome measures were task-dependent hippocampal or parahippocampal activations and precuneus or posterior cingulate deactivations, regional grey matter reductions, CSF Aβ(1-42), total tau and phospho-tau(181) concentrations, and plasma Aβ(1-42) concentrations and Aβ(1-42):Aβ(1-40) ratios. Structural and functional MRI data were compared using automated brain mapping algorithms and search regions related to Alzheimer's disease. Cognitive and fluid biomarkers were compared using Mann-Whitney tests.44 participants were included: 20 PSEN1 E280A mutation carriers and 24 non-carriers. The carrier and non-carrier groups did not differ significantly in their dementia ratings, neuropsychological test scores, or proportion of apolipoprotein E (APOE) ɛ4 carriers. Compared with non-carriers, carriers had greater right hippocampal and parahippocampal activation (p=0·001 and p<0·014, respectively, after correction for multiple comparisons), less precuneus and posterior cingulate deactivation (all p<0·010 after correction), and less grey matter in several parietal regions (all p<0·002 uncorrected and corrected p=0·009 in the right parietal search region). In the 20 participants (ten PSEN1 E280A mutation carriers and ten non-carriers) who had lumbar punctures and venepunctures, mutation carriers had higher CSF Aβ(1-42) concentrations (p=0·008) and plasma Aβ(1-42) concentrations (p=0·01) than non-carriers.FINDINGS44 participants were included: 20 PSEN1 E280A mutation carriers and 24 non-carriers. The carrier and non-carrier groups did not differ significantly in their dementia ratings, neuropsychological test scores, or proportion of apolipoprotein E (APOE) ɛ4 carriers. Compared with non-carriers, carriers had greater right hippocampal and parahippocampal activation (p=0·001 and p<0·014, respectively, after correction for multiple comparisons), less precuneus and posterior cingulate deactivation (all p<0·010 after correction), and less grey matter in several parietal regions (all p<0·002 uncorrected and corrected p=0·009 in the right parietal search region). In the 20 participants (ten PSEN1 E280A mutation carriers and ten non-carriers) who had lumbar punctures and venepunctures, mutation carriers had higher CSF Aβ(1-42) concentrations (p=0·008) and plasma Aβ(1-42) concentrations (p=0·01) than non-carriers.Young adults at genetic risk for autosomal dominant Alzheimer's disease have functional and structural MRI findings and CSF and plasma biomarker findings consistent with Aβ(1-42) overproduction. Although the extent to which the underlying brain changes are either neurodegenerative or developmental remain to be determined, this study shows the earliest known biomarker changes in cognitively normal people at genetic risk for autosomal dominant Alzheimer's disease.INTERPRETATIONYoung adults at genetic risk for autosomal dominant Alzheimer's disease have functional and structural MRI findings and CSF and plasma biomarker findings consistent with Aβ(1-42) overproduction. Although the extent to which the underlying brain changes are either neurodegenerative or developmental remain to be determined, this study shows the earliest known biomarker changes in cognitively normal people at genetic risk for autosomal dominant Alzheimer's disease.Banner Alzheimer's Foundation, Nomis Foundation, Anonymous Foundation, Forget Me Not Initiative, Boston University Department of Psychology, Colciencias, National Institute on Aging, National Institute of Neurological Disorders and Stroke, and the State of Arizona.FUNDINGBanner Alzheimer's Foundation, Nomis Foundation, Anonymous Foundation, Forget Me Not Initiative, Boston University Department of Psychology, Colciencias, National Institute on Aging, National Institute of Neurological Disorders and Stroke, and the State of Arizona. We have previously characterised functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's disease. To gain further knowledge on the preclinical phase of Alzheimer's disease, we sought to characterise structural and functional MRI, CSF, and plasma biomarkers in a cohort of young adults carrying a high-penetrance autosomal dominant mutation that causes early-onset Alzheimer's disease. Between January and August, 2010, 18-26-year-old presenilin 1 (PSEN1) E280A mutation carriers and non-carriers from the Colombian Alzheimer's Prevention Initiative Registry in Medellín Antioquia, Colombia, had structural MRI, functional MRI during associative memory encoding and novel viewing and control tasks, and cognitive assessments. Consenting participants also had lumbar punctures and venepunctures. Outcome measures were task-dependent hippocampal or parahippocampal activations and precuneus or posterior cingulate deactivations, regional grey matter reductions, CSF Aβ(1-42), total tau and phospho-tau(181) concentrations, and plasma Aβ(1-42) concentrations and Aβ(1-42):Aβ(1-40) ratios. Structural and functional MRI data were compared using automated brain mapping algorithms and search regions related to Alzheimer's disease. Cognitive and fluid biomarkers were compared using Mann-Whitney tests. 44 participants were included: 20 PSEN1 E280A mutation carriers and 24 non-carriers. The carrier and non-carrier groups did not differ significantly in their dementia ratings, neuropsychological test scores, or proportion of apolipoprotein E (APOE) ɛ4 carriers. Compared with non-carriers, carriers had greater right hippocampal and parahippocampal activation (p=0·001 and p<0·014, respectively, after correction for multiple comparisons), less precuneus and posterior cingulate deactivation (all p<0·010 after correction), and less grey matter in several parietal regions (all p<0·002 uncorrected and corrected p=0·009 in the right parietal search region). In the 20 participants (ten PSEN1 E280A mutation carriers and ten non-carriers) who had lumbar punctures and venepunctures, mutation carriers had higher CSF Aβ(1-42) concentrations (p=0·008) and plasma Aβ(1-42) concentrations (p=0·01) than non-carriers. Young adults at genetic risk for autosomal dominant Alzheimer's disease have functional and structural MRI findings and CSF and plasma biomarker findings consistent with Aβ(1-42) overproduction. Although the extent to which the underlying brain changes are either neurodegenerative or developmental remain to be determined, this study shows the earliest known biomarker changes in cognitively normal people at genetic risk for autosomal dominant Alzheimer's disease. Banner Alzheimer's Foundation, Nomis Foundation, Anonymous Foundation, Forget Me Not Initiative, Boston University Department of Psychology, Colciencias, National Institute on Aging, National Institute of Neurological Disorders and Stroke, and the State of Arizona. |
| Author | Velez-Pardo, Carlos Langbaum, Jessica BS Quiroz, Yakeel T Munoz, Claudia Lopera, Francisco Reiman, Eric M Kosik, Kenneth S Fleisher, Adam S Shah, Aarti R Reiman, Rebecca A Alexander, Gene E Chen, Kewei Huentelman, Matthew J Jimenez-Del-Rio, Marlene Fagan, Anne M Giraldo, Margarita Tirado, Victoria Alvarez, Sergio Stern, Chantal E Tariot, Pierre N Arbelaez, Andrés Acosta-Baena, Natalia Sperling, Reisa A Dickerson, Brad |
| Author_xml | – sequence: 1 givenname: Eric M surname: Reiman fullname: Reiman, Eric M email: eric.reiman@bannerhealth.com organization: Banner Alzheimer's Institute, Phoenix, AZ, USA – sequence: 2 givenname: Yakeel T surname: Quiroz fullname: Quiroz, Yakeel T organization: Center for Memory and Brain, Psychology Department, Boston University, Boston, MA, USA – sequence: 3 givenname: Adam S surname: Fleisher fullname: Fleisher, Adam S organization: Banner Alzheimer's Institute, Phoenix, AZ, USA – sequence: 4 givenname: Kewei surname: Chen fullname: Chen, Kewei organization: Department of Radiology, University of Arizona, Phoenix and Tucson, AZ, USA – sequence: 5 givenname: Carlos surname: Velez-Pardo fullname: Velez-Pardo, Carlos organization: University of Antioquia, Medellin, Colombia – sequence: 6 givenname: Marlene surname: Jimenez-Del-Rio fullname: Jimenez-Del-Rio, Marlene organization: University of Antioquia, Medellin, Colombia – sequence: 7 givenname: Anne M surname: Fagan fullname: Fagan, Anne M organization: Department of Neurology, Washington University School of Medicine, St Louis, MO, USA – sequence: 8 givenname: Aarti R surname: Shah fullname: Shah, Aarti R organization: Department of Neurology, Washington University School of Medicine, St Louis, MO, USA – sequence: 9 givenname: Sergio surname: Alvarez fullname: Alvarez, Sergio organization: Hospital Pablo Tobón Uribe, Medellin, Colombia – sequence: 10 givenname: Andrés surname: Arbelaez fullname: Arbelaez, Andrés organization: Hospital Pablo Tobón Uribe, Medellin, Colombia – sequence: 11 givenname: Margarita surname: Giraldo fullname: Giraldo, Margarita organization: University of Antioquia, Medellin, Colombia – sequence: 12 givenname: Natalia surname: Acosta-Baena fullname: Acosta-Baena, Natalia organization: University of Antioquia, Medellin, Colombia – sequence: 13 givenname: Reisa A surname: Sperling fullname: Sperling, Reisa A organization: Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA – sequence: 14 givenname: Brad surname: Dickerson fullname: Dickerson, Brad organization: Department of Neurology, Massachusetts General Hospital, Boston, MA, USA – sequence: 15 givenname: Chantal E surname: Stern fullname: Stern, Chantal E organization: Center for Memory and Brain, Psychology Department, Boston University, Boston, MA, USA – sequence: 16 givenname: Victoria surname: Tirado fullname: Tirado, Victoria organization: University of Antioquia, Medellin, Colombia – sequence: 17 givenname: Claudia surname: Munoz fullname: Munoz, Claudia organization: University of Antioquia, Medellin, Colombia – sequence: 18 givenname: Rebecca A surname: Reiman fullname: Reiman, Rebecca A organization: Neurogenomics Division, Translational Genomics Research Institute, Phoenix, AZ, USA – sequence: 19 givenname: Matthew J surname: Huentelman fullname: Huentelman, Matthew J organization: Neurogenomics Division, Translational Genomics Research Institute, Phoenix, AZ, USA – sequence: 20 givenname: Gene E surname: Alexander fullname: Alexander, Gene E organization: Department of Psychology, University of Arizona, Phoenix and Tucson, AZ, USA – sequence: 21 givenname: Jessica BS surname: Langbaum fullname: Langbaum, Jessica BS organization: Banner Alzheimer's Institute, Phoenix, AZ, USA – sequence: 22 givenname: Kenneth S surname: Kosik fullname: Kosik, Kenneth S organization: Neuroscience Research Institute, University of California, Santa Barbara, Santa Barbara, CA, USA – sequence: 23 givenname: Pierre N surname: Tariot fullname: Tariot, Pierre N organization: Banner Alzheimer's Institute, Phoenix, AZ, USA – sequence: 24 givenname: Francisco surname: Lopera fullname: Lopera, Francisco organization: University of Antioquia, Medellin, Colombia |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23137948$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkl1rFDEYhQep2A_9CUrAC-vFaD5mJ5mKylrqBxS8UK9DNnmnTTeTrElGWP-T_9FMd62wICu5mMzLcw7hnPe4OvDBQ1U9JvgFwaR9-YU0vKmbhtJTQp9zTKmom3vV0Xbczg7u7pQeVscp3WBMSSPIg-qQMsJ414ij6te7qKxHdlBX1l8h5Q3q3WgNWtgwqLiEWGbKrZNNqHDrME6UGV1OSGV0BR6y1SjatER9KPCYQypKh0wYrFc-o7n7eQ12gPgsIWMTqASTVb4GtIqQwFtXfgm6oALP0dJ6E8GcIYV0IWsdfI7BoZRHs35Y3e-VS_Bo-z2pvr2_-Hr-sb78_OHT-fyy1q0gueZYE8VbCv1MdJqJBdUMGCUEqC5DxnrOdb9YMCZaZVhvRNfNzExxShiGMjmpTje-qxi-j5CyHGzS4JzyEMYkCeXTEZTvRwkngjPGRUGf7qA3YYwl3YnqeFu6wV2hnmypcTGAkatYyolr-aezAsw2gI4hpQj9HUKwnHZD3u6GnIovL5W3uyGbonu1o9M2q2yngJV1e9VvN2oouf-wEGXSFrwGYyPoLE2wex3e7DjoUrzVyi1hDelvFjJRiTcmk0cJe3KYDF7_2-A_HvAbjyz7Pg |
| CODEN | LANCAO |
| CitedBy_id | crossref_primary_10_1016_j_neuroimage_2019_116113 crossref_primary_10_1016_j_neuroscience_2022_09_012 crossref_primary_10_1016_j_biopsych_2021_12_015 crossref_primary_10_3389_fnut_2022_1036795 crossref_primary_10_1038_mp_2015_177 crossref_primary_10_3389_fnagi_2022_903269 crossref_primary_10_1016_j_bbr_2022_114218 crossref_primary_10_1093_procel_pwae023 crossref_primary_10_1371_journal_pbio_3001412 crossref_primary_10_3233_JAD_170733 crossref_primary_10_1093_procel_pwae026 crossref_primary_10_7717_peerj_cs_1706 crossref_primary_10_1016_j_neurobiolaging_2014_12_022 crossref_primary_10_3389_fnsyn_2022_826601 crossref_primary_10_1016_j_neurobiolaging_2019_09_005 crossref_primary_10_1111_jnc_16066 crossref_primary_10_1111_jnc_14680 crossref_primary_10_1038_eye_2015_158 crossref_primary_10_1016_j_neurobiolaging_2013_02_013 crossref_primary_10_1212_WNL_0000000000207423 crossref_primary_10_1016_j_jalz_2016_07_005 crossref_primary_10_1016_j_nic_2017_06_005 crossref_primary_10_1016_j_nut_2014_06_016 crossref_primary_10_3233_JAD_160803 crossref_primary_10_3233_JAD_171033 crossref_primary_10_4236_aad_2013_24016 crossref_primary_10_1080_13102818_2021_1964382 crossref_primary_10_1016_j_jalz_2018_12_019 crossref_primary_10_1016_j_neurobiolaging_2016_07_009 crossref_primary_10_1093_hmg_ddaa119 crossref_primary_10_1186_s42492_024_00154_x crossref_primary_10_1523_JNEUROSCI_2552_14_2015 crossref_primary_10_1016_j_neurobiolaging_2017_10_021 crossref_primary_10_1111_jgs_14883 crossref_primary_10_1159_000485899 crossref_primary_10_1002_alz_12068 crossref_primary_10_1016_j_neurobiolaging_2014_07_001 crossref_primary_10_1016_j_neuron_2013_01_002 crossref_primary_10_14283_jpad_2019_6 crossref_primary_10_1007_s00415_013_6921_3 crossref_primary_10_1016_j_ncl_2019_08_003 crossref_primary_10_1586_14737159_2015_1002469 crossref_primary_10_3390_healthcare10050839 crossref_primary_10_2217_nmt_13_68 crossref_primary_10_1007_s10654_017_0331_2 crossref_primary_10_1016_j_bcp_2013_11_009 crossref_primary_10_1016_j_jconrel_2016_11_025 crossref_primary_10_3233_JAD_150586 crossref_primary_10_1001_jamanetworkopen_2023_41388 crossref_primary_10_3233_JAD_200011 crossref_primary_10_1016_S1474_4422_13_70090_5 crossref_primary_10_1016_j_trci_2015_06_004 crossref_primary_10_1002_ana_23908 crossref_primary_10_1016_j_mcpro_2023_100542 crossref_primary_10_1186_s12883_023_03323_2 crossref_primary_10_1186_s13195_016_0172_3 crossref_primary_10_1016_S1474_4422_12_70255_7 crossref_primary_10_1002_alz_12951 crossref_primary_10_1016_j_ncl_2017_01_010 crossref_primary_10_1088_1752_7163_ab6016 crossref_primary_10_1176_appi_focus_20150019 crossref_primary_10_1007_s11910_014_0498_9 crossref_primary_10_1097_MD_0000000000011343 crossref_primary_10_1177_2472630318803277 crossref_primary_10_1016_j_ijpharm_2024_124002 crossref_primary_10_1016_j_jalz_2018_07_220 crossref_primary_10_1186_1750_1326_8_20 crossref_primary_10_1177_1073858414545999 crossref_primary_10_1371_journal_pone_0227258 crossref_primary_10_1093_brain_awv199 crossref_primary_10_1093_braincomms_fcaf018 crossref_primary_10_3233_JAD_143006 crossref_primary_10_1007_s41133_019_0021_6 crossref_primary_10_1038_s41598_020_68739_z crossref_primary_10_1111_jnc_14589 crossref_primary_10_3389_fneur_2025_1534193 crossref_primary_10_1002_alz_13809 crossref_primary_10_1080_21507740_2021_1941412 crossref_primary_10_3233_JAD_150214 crossref_primary_10_3389_fnagi_2021_720990 crossref_primary_10_2174_1871527321666220901125730 crossref_primary_10_3390_antiox9090818 crossref_primary_10_14283_jpad_2018_42 crossref_primary_10_1038_s41598_024_76313_0 crossref_primary_10_1159_000533283 crossref_primary_10_1177_1755738018759700 crossref_primary_10_1371_journal_pone_0080355 crossref_primary_10_1016_j_jalz_2015_02_003 crossref_primary_10_1097_WAD_0000000000000237 crossref_primary_10_1007_s00401_013_1151_4 crossref_primary_10_1016_j_arr_2016_01_004 crossref_primary_10_1001_jamaophthalmol_2020_4909 crossref_primary_10_1016_j_ynirp_2021_100059 crossref_primary_10_14283_jpad_2018_49 crossref_primary_10_1186_s40478_020_01102_5 crossref_primary_10_1002_alz_13016 crossref_primary_10_1057_biosoc_2013_5 crossref_primary_10_2217_nmt_14_19 crossref_primary_10_1002_alz_12843 crossref_primary_10_1186_s13195_014_0087_9 crossref_primary_10_4236_aad_2023_122002 crossref_primary_10_1177_1533317513520214 crossref_primary_10_3233_JAD_190442 crossref_primary_10_1007_s40495_021_00265_6 crossref_primary_10_1038_nrneurol_2013_107 crossref_primary_10_1038_nrdp_2015_56 crossref_primary_10_1002_slct_202400684 crossref_primary_10_1159_000496100 crossref_primary_10_1038_s41598_021_85912_0 crossref_primary_10_1186_s13024_018_0264_6 crossref_primary_10_3390_molecules24030446 crossref_primary_10_1186_alzrt162 crossref_primary_10_1007_s00044_025_03373_w crossref_primary_10_1212_WNL_0b013e3182a841c6 crossref_primary_10_1016_j_nicl_2013_02_006 crossref_primary_10_1172_JCI129788 crossref_primary_10_1002_dad2_12233 crossref_primary_10_1016_j_neuron_2013_12_003 crossref_primary_10_1523_JNEUROSCI_5441_13_2014 crossref_primary_10_1016_j_jalz_2019_01_010 crossref_primary_10_1016_j_jbi_2021_103978 crossref_primary_10_1186_s13195_024_01574_w crossref_primary_10_3390_endocrines5020014 crossref_primary_10_3389_fnins_2024_1402657 crossref_primary_10_1038_d41586_018_03848_4 crossref_primary_10_1016_j_arr_2016_10_001 crossref_primary_10_1080_14712598_2018_1389885 crossref_primary_10_1016_j_jbior_2017_01_001 crossref_primary_10_1016_j_isci_2020_101468 crossref_primary_10_1016_j_neurobiolaging_2014_05_019 crossref_primary_10_3389_fncel_2015_00318 crossref_primary_10_1093_braincomms_fcad229 crossref_primary_10_1038_s43587_024_00735_8 crossref_primary_10_1038_s41598_020_80312_2 crossref_primary_10_1093_brain_awt065 crossref_primary_10_1016_j_jalz_2016_01_009 crossref_primary_10_1093_brain_awv007 crossref_primary_10_1038_nrneurol_2013_21 crossref_primary_10_3390_sym17020172 crossref_primary_10_1038_nrneurol_2015_177 crossref_primary_10_1016_j_neurobiolaging_2013_09_028 crossref_primary_10_1038_s42003_021_02558_4 crossref_primary_10_1007_s13311_021_01026_5 crossref_primary_10_3233_JAD_191334 crossref_primary_10_1002_adtp_202000076 crossref_primary_10_1021_cbmi_3c00056 crossref_primary_10_3389_fnagi_2016_00304 crossref_primary_10_4236_wjns_2017_71010 crossref_primary_10_1167_tvst_9_5_18 crossref_primary_10_3390_healthcare9020157 crossref_primary_10_1007_s15005_013_0108_4 crossref_primary_10_1016_j_arr_2024_102632 crossref_primary_10_1111_ejn_12181 crossref_primary_10_3389_fneur_2024_1445479 crossref_primary_10_47795_DAKX8027 crossref_primary_10_1038_s41380_021_01249_0 crossref_primary_10_1038_nrn3505 crossref_primary_10_3233_JAD_210148 crossref_primary_10_3390_jpm11010047 crossref_primary_10_1016_j_expneurol_2021_113969 crossref_primary_10_1093_brain_awab166 crossref_primary_10_1007_s12035_018_1298_z crossref_primary_10_1002_alz_12757 crossref_primary_10_1002_alz_12638 crossref_primary_10_1016_j_neuroimage_2016_11_056 crossref_primary_10_1155_2013_579136 crossref_primary_10_1016_j_jalz_2017_02_001 crossref_primary_10_1177_10738584221118262 crossref_primary_10_31083_j_jin2308143 crossref_primary_10_1016_S1474_4422_12_70227_2 crossref_primary_10_1016_j_neurobiolaging_2022_05_005 crossref_primary_10_3390_jcm3041402 crossref_primary_10_1021_cn500101j crossref_primary_10_1007_s40291_013_0069_9 crossref_primary_10_3389_fnagi_2020_524024 crossref_primary_10_1021_acsomega_9b01557 crossref_primary_10_1097_WCO_0000000000000109 crossref_primary_10_1080_13803395_2018_1438372 crossref_primary_10_2147_NRR_S339200 crossref_primary_10_4103_ni_ni_1073_22 crossref_primary_10_1002_alz_12328 crossref_primary_10_1364_OPTCON_471544 crossref_primary_10_1016_S1474_4422_12_70284_3 crossref_primary_10_1016_j_maturitas_2022_10_012 crossref_primary_10_1186_s13195_014_0060_7 crossref_primary_10_1186_s13195_021_00804_9 crossref_primary_10_1093_brain_awx194 crossref_primary_10_1186_s12974_021_02320_x crossref_primary_10_1093_gerona_glab047 crossref_primary_10_1016_j_trci_2016_09_003 crossref_primary_10_5851_kosfa_2024_e5 crossref_primary_10_1016_j_jalz_2016_09_010 crossref_primary_10_1126_scitranslmed_3005615 crossref_primary_10_1186_s13195_019_0572_2 crossref_primary_10_3389_fnins_2022_798994 crossref_primary_10_1016_j_cct_2013_06_012 crossref_primary_10_1016_S2666_7568_24_00132_6 crossref_primary_10_3389_fnagi_2020_578071 crossref_primary_10_1016_j_neuron_2014_10_038 crossref_primary_10_1093_brain_awu367 crossref_primary_10_1016_j_jalz_2013_08_282 crossref_primary_10_3390_life11080750 crossref_primary_10_1093_brain_awz019 crossref_primary_10_1111_nyas_12138 crossref_primary_10_3233_JAD_170585 crossref_primary_10_3389_fnmol_2015_00047 crossref_primary_10_3390_e19030129 crossref_primary_10_1016_j_jth_2020_100992 crossref_primary_10_1111_cns_14818 crossref_primary_10_1212_WNL_0000000000006277 crossref_primary_10_1007_s12035_017_0580_9 crossref_primary_10_1016_j_jalz_2014_02_001 crossref_primary_10_3233_JAD_161291 crossref_primary_10_1159_000358800 crossref_primary_10_1016_j_nantod_2022_101536 crossref_primary_10_1523_JNEUROSCI_1397_18_2018 crossref_primary_10_1016_j_jalz_2018_02_001 crossref_primary_10_1016_S1474_4422_14_70090_0 crossref_primary_10_1186_s13195_019_0487_y crossref_primary_10_1126_scitranslmed_3007901 crossref_primary_10_1002_alz_12224 crossref_primary_10_1002_alz_12227 crossref_primary_10_5665_sleep_5846 crossref_primary_10_1016_j_ejmech_2019_111651 crossref_primary_10_1038_nrn_2016_141 crossref_primary_10_1016_j_ibror_2018_01_003 crossref_primary_10_1097_YCO_0b013e32835f6747 crossref_primary_10_1017_S1355617721000916 crossref_primary_10_1038_mp_2013_142 crossref_primary_10_1109_ACCESS_2019_2919385 crossref_primary_10_1186_s13195_015_0169_3 crossref_primary_10_1371_journal_pone_0221669 crossref_primary_10_3233_JAD_201184 crossref_primary_10_1177_23982128241280001 crossref_primary_10_1007_s00401_022_02458_9 crossref_primary_10_1186_s13148_020_00916_3 crossref_primary_10_7554_eLife_57354 crossref_primary_10_1016_j_bionps_2023_100068 crossref_primary_10_1371_journal_pone_0084547 crossref_primary_10_1016_j_ejrad_2017_07_006 crossref_primary_10_1017_cjn_2023_322 crossref_primary_10_1155_2013_689591 crossref_primary_10_1016_j_neubiorev_2021_12_010 crossref_primary_10_1159_000381828 crossref_primary_10_1590_1980_5764_dn_2024_im01 crossref_primary_10_3233_JAD_191261 crossref_primary_10_3389_fnins_2015_00423 crossref_primary_10_1002_ange_201209885 crossref_primary_10_1016_j_neurobiolaging_2013_12_030 crossref_primary_10_1073_pnas_1525466113 crossref_primary_10_1186_alzrt197 crossref_primary_10_1007_s11682_016_9556_z crossref_primary_10_1155_2014_826503 crossref_primary_10_1093_hmg_ddab262 crossref_primary_10_1016_j_talanta_2022_123526 crossref_primary_10_1016_j_nbas_2023_100091 crossref_primary_10_1186_s13195_022_01017_4 crossref_primary_10_3233_JAD_215464 crossref_primary_10_1212_WNL_0b013e3182a1aafe crossref_primary_10_1093_brain_awy050 crossref_primary_10_1002_anie_201209885 crossref_primary_10_1007_s11356_022_23703_4 crossref_primary_10_1016_j_hermed_2019_100291 crossref_primary_10_1093_braincomms_fcad245 crossref_primary_10_1021_acschemneuro_7b00260 crossref_primary_10_1038_nrneurol_2015_119 crossref_primary_10_1093_brain_awt168 crossref_primary_10_1007_s11910_017_0718_1 crossref_primary_10_1007_s12017_014_8302_1 crossref_primary_10_1038_s41598_017_15001_8 crossref_primary_10_1212_WNL_0000000000002683 crossref_primary_10_1186_s40708_022_00168_2 crossref_primary_10_1155_2013_257953 crossref_primary_10_1016_j_jalz_2013_04_506 crossref_primary_10_1038_ncomms10918 crossref_primary_10_1001_jamaoto_2019_1610 crossref_primary_10_1016_S1474_4422_21_00375_6 crossref_primary_10_1080_13813455_2020_1722707 crossref_primary_10_3390_biomedicines11020355 crossref_primary_10_1016_j_neuroimage_2014_10_050 crossref_primary_10_1136_bmjopen_2023_076005 crossref_primary_10_1016_S1474_4422_12_70256_9 crossref_primary_10_1038_s41401_023_01125_3 crossref_primary_10_1093_brain_awy244 crossref_primary_10_3389_fnagi_2017_00016 crossref_primary_10_1111_cns_12260 crossref_primary_10_3389_fncel_2021_782768 crossref_primary_10_1016_j_mayocp_2017_02_011 crossref_primary_10_1097_WCO_0000000000000029 crossref_primary_10_1016_j_brainres_2016_05_026 crossref_primary_10_1021_acs_inorgchem_9b00507 crossref_primary_10_1088_1361_6528_ab7535 crossref_primary_10_3233_JAD_191065 crossref_primary_10_3389_fncel_2018_00317 crossref_primary_10_3389_fnagi_2014_00032 crossref_primary_10_3390_diagnostics8030047 crossref_primary_10_1186_s13195_020_00646_x crossref_primary_10_3390_ijms22031102 crossref_primary_10_1186_alzrt213 crossref_primary_10_2217_bmm_2016_0276 crossref_primary_10_3389_fnins_2022_837390 crossref_primary_10_2174_1570159X19666210517114016 crossref_primary_10_1016_j_jmb_2019_01_023 crossref_primary_10_1016_j_jns_2024_123361 crossref_primary_10_3233_JAD_160434 crossref_primary_10_3389_fnmol_2020_600084 crossref_primary_10_1017_S1041610216000624 crossref_primary_10_3233_JAD_200835 crossref_primary_10_1080_13557858_2023_2231669 crossref_primary_10_1177_1073858413494270 crossref_primary_10_1016_j_bcp_2012_11_014 crossref_primary_10_1177_0300060520902895 crossref_primary_10_1523_ENEURO_0132_17_2018 crossref_primary_10_3390_s21124249 crossref_primary_10_1016_j_pneurobio_2013_08_003 crossref_primary_10_1016_j_tibtech_2017_06_002 crossref_primary_10_1038_s41467_021_25492_9 crossref_primary_10_1126_scitranslmed_3007941 crossref_primary_10_1016_j_cortex_2016_01_015 crossref_primary_10_1016_j_neuroscience_2018_09_016 crossref_primary_10_1089_neu_2020_7386 crossref_primary_10_1186_s13195_022_01041_4 crossref_primary_10_3233_JAD_160907 crossref_primary_10_1038_nrneurol_2012_243 crossref_primary_10_1093_braincomms_fcac182 crossref_primary_10_1021_acs_inorgchem_2c01694 crossref_primary_10_3390_nu8020099 crossref_primary_10_1177_2053369119883485 crossref_primary_10_3390_molecules22101723 crossref_primary_10_1093_cercor_bhu286 crossref_primary_10_3390_diagnostics11050887 crossref_primary_10_1007_s11481_014_9546_0 crossref_primary_10_1186_1471_244X_13_76 crossref_primary_10_1016_j_tem_2016_12_001 crossref_primary_10_1016_j_inffus_2020_01_001 crossref_primary_10_1016_j_nbd_2017_07_013 crossref_primary_10_1016_j_trci_2017_04_006 crossref_primary_10_1016_S0140_6736_20_30689_9 crossref_primary_10_21307_ane_2020_021 crossref_primary_10_1016_j_jpba_2021_114479 crossref_primary_10_1016_j_arr_2021_101389 crossref_primary_10_3389_fnins_2018_00275 crossref_primary_10_1016_j_jalz_2016_03_001 crossref_primary_10_3390_ijms24076790 crossref_primary_10_1038_srep29078 crossref_primary_10_1016_j_mcna_2012_12_012 crossref_primary_10_14412_2074_2711_2023_2_63_67 crossref_primary_10_3233_JAD_150899 crossref_primary_10_1001_jamapsychiatry_2019_3120 crossref_primary_10_3233_JAD_150897 crossref_primary_10_1038_s41514_024_00169_x crossref_primary_10_2217_WHE_13_22 crossref_primary_10_1088_2057_1976_ab501c crossref_primary_10_1186_s13195_022_01030_7 crossref_primary_10_1016_j_biopha_2020_110887 crossref_primary_10_1097_WAD_0000000000000157 crossref_primary_10_1111_joim_13332 crossref_primary_10_1016_j_phymed_2020_153244 crossref_primary_10_1016_j_nbd_2022_105980 crossref_primary_10_1084_jem_20171487 crossref_primary_10_1093_brain_awab319 crossref_primary_10_1016_j_trci_2016_02_003 crossref_primary_10_1111_jnc_15762 crossref_primary_10_3389_fnagi_2017_00003 crossref_primary_10_1186_s13195_023_01256_z crossref_primary_10_1212_WNL_0000000000001209 crossref_primary_10_1073_pnas_1317918110 crossref_primary_10_1038_mp_2016_242 crossref_primary_10_18632_aging_205057 |
| Cites_doi | 10.1016/j.neuron.2005.10.028 10.1056/NEJMoa1202753 10.1001/archneur.64.3.noc60123 10.1038/nn.2476 10.1016/S1474-4422(09)70299-6 10.1006/nimg.2001.0848 10.1038/emboj.2012.79 10.1016/S1474-4422(07)70106-0 10.1074/jbc.M209252200 10.1016/S1474-4422(12)70227-2 10.1016/j.jalz.2011.05.618 10.1002/ana.22105 10.1038/nn.2801 10.1073/pnas.0811879106 10.1017/S1041610203009591 10.1016/j.neurobiolaging.2009.11.013 10.1159/000335729 10.1016/j.jalz.2011.03.003 10.1073/pnas.1010461107 10.1186/alzrt59 10.1523/JNEUROSCI.2250-06.2006 10.1093/cercor/bhn113 10.1073/pnas.2635903100 10.3233/JAD-2010-100129 10.1093/brain/awl266 10.33588/rn.4511.2007086 10.1523/JNEUROSCI.2177-05.2005 10.1056/NEJM199603213341202 10.1212/01.wnl.0000303973.71803.81 10.1001/jama.1997.03540340027028 10.1002/ana.20730 10.1016/S1474-4422(10)70323-9 10.1126/science.1072994 |
| ContentType | Journal Article |
| Copyright | 2012 Elsevier Ltd Elsevier Ltd Copyright © 2012 Elsevier Ltd. All rights reserved. |
| Copyright_xml | – notice: 2012 Elsevier Ltd – notice: Elsevier Ltd – notice: Copyright © 2012 Elsevier Ltd. All rights reserved. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 0TZ 3V. 7RV 7TK 7X7 7XB 88E 88G 8AO 8C2 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ K9. KB0 M0S M1P M2M NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS PSYQQ Q9U 7X8 8FD FR3 P64 RC3 |
| DOI | 10.1016/S1474-4422(12)70228-4 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Pharma and Biotech Premium PRO ProQuest Central (Corporate) Nursing & Allied Health Database Neurosciences Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Psychology Database (Alumni) ProQuest Pharma Collection Lancet Titles Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central (New) (NC LIVE) ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni) Medical Database Psychology Database Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic MEDLINE - Academic Technology Research Database Engineering Research Database Biotechnology and BioEngineering Abstracts Genetics Abstracts |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology Pharma and Biotech Premium PRO ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials Lancet Titles ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Psychology Journals (Alumni) Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest Psychology Journals ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic Genetics Abstracts Engineering Research Database Technology Research Database Biotechnology and BioEngineering Abstracts |
| DatabaseTitleList | ProQuest One Psychology Genetics Abstracts MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1474-4465 |
| EndPage | 1056 |
| ExternalDocumentID | 2824714951 23137948 10_1016_S1474_4422_12_70228_4 S1474442212702284 1_s2_0_S1474442212702284 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation | Banner Alzheimer's Foundation, Nomis Foundation, Anonymous Foundation, Forget Me Not Initiative, Boston University Department of Psychology, Colciencias, National Institute on Aging, National Institute of Neurological Disorders and Stroke, and the State of Arizona. |
| GrantInformation_xml | – fundername: NINDS NIH HHS grantid: F31 NS078786 – fundername: NINDS NIH HHS grantid: F31-NS078786 – fundername: NIA NIH HHS grantid: R01 AG025526 – fundername: NIA NIH HHS grantid: R01 AG031581 – fundername: NIA NIH HHS grantid: RF1 AG041705 – fundername: NIA NIH HHS grantid: P30 AG19610 – fundername: NIA NIH HHS grantid: P30 AG019610 – fundername: NIA NIH HHS grantid: RF1AG041705 – fundername: NIA NIH HHS grantid: U01 AG024904 – fundername: NIA NIH HHS grantid: U19 AG024904 |
| GroupedDBID | --- --K --M -RU .1- .FO 0R~ 123 1B1 1P~ 1~5 29L 4.4 457 4G. 53G 5VS 7-5 71M 7RV 7X7 88E 8AO 8C2 8FI 8FJ AAEDT AAEDW AAIKJ AAKOC AALRI AAMRU AAQFI AAQQT AATTM AAXKI AAXLA AAXUO AAYWO ABBQC ABCQJ ABIVO ABJNI ABMAC ABMZM ABOCM ABTEW ABUWG ABWVN ACGFS ACIEU ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADMUD ADNMO AEIPS AEKER AENEX AEUPX AEVXI AFKRA AFPUW AFRHN AFTJW AFXIZ AGCQF AGHFR AGWIK AHMBA AIGII AIIUN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANZVX APXCP AXJTR AZQEC BENPR BKEYQ BKOJK BNPGV BPHCQ BVXVI CCPQU CS3 DU5 DWQXO EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FIRID FNPLU FYGXN FYUFA G-Q GBLVA GNUQQ HF~ HMCUK HVGLF HZ~ IHE J1W JCF KOM M1P M2M M41 MO0 N9A NAPCQ O-L O9- OP~ OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO PSYQQ PUEGO ROL RPZ SDG SEL SES SPCBC SSH SSN SSZ T5K TLN UHS UKHRP UV1 WOW XBR Z5R 3V. AACTN AFCTW AFKWA AJOXV ALIPV AMFUW RIG SDF AADPK ABLVK ABYKQ AJBFU ZA5 AAYXX AGRNS CITATION CGR CUY CVF ECM EIF NPM 0TZ 7TK 7XB 8FK K9. PKEHL PQEST PQUKI PRINS Q9U 7X8 8FD FR3 P64 RC3 |
| ID | FETCH-LOGICAL-c681t-70c1a762ef589c38b2c3e3211e2c2ef33f77cfbb3386ad3fd8995d5a72130ead3 |
| IEDL.DBID | 7X7 |
| ISSN | 1474-4422 1474-4465 |
| IngestDate | Mon Jul 21 10:43:13 EDT 2025 Thu Jul 10 19:29:08 EDT 2025 Fri Jul 25 04:17:35 EDT 2025 Mon Jul 21 06:06:51 EDT 2025 Tue Jul 01 05:15:18 EDT 2025 Thu Apr 24 23:00:18 EDT 2025 Fri Feb 23 02:28:58 EST 2024 Sun Feb 23 10:18:51 EST 2025 Tue Aug 26 17:49:12 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 12 |
| Language | English |
| License | https://www.elsevier.com/tdm/userlicense/1.0 Copyright © 2012 Elsevier Ltd. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c681t-70c1a762ef589c38b2c3e3211e2c2ef33f77cfbb3386ad3fd8995d5a72130ead3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Undefined-1 ObjectType-Feature-3 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 ObjectType-Feature-1 |
| OpenAccessLink | http://doi.org/10.1016/S1474-4422(12)70228-4 |
| PMID | 23137948 |
| PQID | 1197648109 |
| PQPubID | 26255 |
| PageCount | 9 |
| ParticipantIDs | proquest_miscellaneous_1272727827 proquest_miscellaneous_1171873378 proquest_journals_1197648109 pubmed_primary_23137948 crossref_primary_10_1016_S1474_4422_12_70228_4 crossref_citationtrail_10_1016_S1474_4422_12_70228_4 elsevier_sciencedirect_doi_10_1016_S1474_4422_12_70228_4 elsevier_clinicalkeyesjournals_1_s2_0_S1474442212702284 elsevier_clinicalkey_doi_10_1016_S1474_4422_12_70228_4 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2012-12-01 |
| PublicationDateYYYYMMDD | 2012-12-01 |
| PublicationDate_xml | – month: 12 year: 2012 text: 2012-12-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | Lancet neurology |
| PublicationTitleAlternate | Lancet Neurol |
| PublicationYear | 2012 |
| Publisher | Elsevier Ltd Elsevier Limited |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited |
| References | Silvia (bib21) 2003; 15 Knight, Kim, Douiri, Frost, Rossor, Fox (bib17) 2011; 32 Baron, Chetelat, Desgranges (bib35) 2001; 14 Sperling, Aisen, Beckett (bib4) 2011; 7 Chavez-Gutierrez, Bammens, Benilova (bib10) 2012; 31 Bateman, Aisen, De Strooper (bib8) 2011; 3 Ringman, Younkin, Pratico (bib9) 2008; 71 Shaw, Lerch, Pruessner (bib7) 2007; 6 Lopera, Ardilla, Martinez (bib12) 1997; 277 Talairach, Tournoux (bib22) 1988 Valla, Yaari, Wolf (bib6) 2010; 22 Vlassenko, Vaishnavi, Couture (bib29) 2010; 107 Bero, Yan, Roh (bib32) 2011; 14 Cirrito, Yamada, Finn (bib33) 2005; 48 Quiroz, Stern, Reiman (bib15) 2011; 7 Aguirre-Acevedo, Gomez, Moreno (bib20) 2007; 45 Mosconi, Sorbi, de Leon (bib34) 2006; 47 Wei, Nguyen, Kessels, Hagiwara, Sisodia, Malinow (bib31) 2010; 13 Filippini, MacIntosh, Hough (bib3) 2009; 106 Celone, Calhoun, Dickerson (bib18) 2006; 26 Ringman, Coppola, Elashoff (bib24) 2012; 33 Acosta-Baena, Sepulveda-Falla, Lopera-Gomez (bib13) 2011; 10 Quiroz, Budson, Celone (bib14) 2010; 68 Mondadori, Buchmann, Mustovic (bib16) 2006; 129 Buckner, Snyder, Shannon (bib30) 2005; 25 Jack, Knopman, Jagust (bib2) 2010; 9 Fleisher, Chen, Quiroz (bib27) 2012 Reiman, Chen, Alexander (bib5) 2004; 101 Bateman, Xiong, Benzinger (bib11) 2012; 367 Fagan, Roe, Xiong, Mintun, Morris, Holtzman (bib23) 2007; 64 Ikeuchi, Dolios, Kim, Wang, Sisodia (bib25) 2003; 278 Fagan, Mintun, Mach (bib26) 2006; 59 Reiman, Caselli, Yun (bib28) 1996; 334 Dickerson, Bakkour, Salat (bib19) 2009; 19 Hardy, Selkoe (bib1) 2002; 297 Cirrito (10.1016/S1474-4422(12)70228-4_bib33) 2005; 48 Wei (10.1016/S1474-4422(12)70228-4_bib31) 2010; 13 Talairach (10.1016/S1474-4422(12)70228-4_bib22) 1988 Baron (10.1016/S1474-4422(12)70228-4_bib35) 2001; 14 Mondadori (10.1016/S1474-4422(12)70228-4_bib16) 2006; 129 Quiroz (10.1016/S1474-4422(12)70228-4_bib14) 2010; 68 Filippini (10.1016/S1474-4422(12)70228-4_bib3) 2009; 106 Bateman (10.1016/S1474-4422(12)70228-4_bib11) 2012; 367 Acosta-Baena (10.1016/S1474-4422(12)70228-4_bib13) 2011; 10 Ringman (10.1016/S1474-4422(12)70228-4_bib9) 2008; 71 Bero (10.1016/S1474-4422(12)70228-4_bib32) 2011; 14 Chavez-Gutierrez (10.1016/S1474-4422(12)70228-4_bib10) 2012; 31 Ringman (10.1016/S1474-4422(12)70228-4_bib24) 2012; 33 Quiroz (10.1016/S1474-4422(12)70228-4_bib15) 2011; 7 Knight (10.1016/S1474-4422(12)70228-4_bib17) 2011; 32 Aguirre-Acevedo (10.1016/S1474-4422(12)70228-4_bib20) 2007; 45 Fleisher (10.1016/S1474-4422(12)70228-4_bib27) 2012 Buckner (10.1016/S1474-4422(12)70228-4_bib30) 2005; 25 Reiman (10.1016/S1474-4422(12)70228-4_bib5) 2004; 101 Celone (10.1016/S1474-4422(12)70228-4_bib18) 2006; 26 Hardy (10.1016/S1474-4422(12)70228-4_bib1) 2002; 297 Jack (10.1016/S1474-4422(12)70228-4_bib2) 2010; 9 Sperling (10.1016/S1474-4422(12)70228-4_bib4) 2011; 7 Fagan (10.1016/S1474-4422(12)70228-4_bib23) 2007; 64 Ikeuchi (10.1016/S1474-4422(12)70228-4_bib25) 2003; 278 Lopera (10.1016/S1474-4422(12)70228-4_bib12) 1997; 277 Valla (10.1016/S1474-4422(12)70228-4_bib6) 2010; 22 Bateman (10.1016/S1474-4422(12)70228-4_bib8) 2011; 3 Shaw (10.1016/S1474-4422(12)70228-4_bib7) 2007; 6 Fagan (10.1016/S1474-4422(12)70228-4_bib26) 2006; 59 Mosconi (10.1016/S1474-4422(12)70228-4_bib34) 2006; 47 Vlassenko (10.1016/S1474-4422(12)70228-4_bib29) 2010; 107 Dickerson (10.1016/S1474-4422(12)70228-4_bib19) 2009; 19 Reiman (10.1016/S1474-4422(12)70228-4_bib28) 1996; 334 Silvia (10.1016/S1474-4422(12)70228-4_bib21) 2003; 15 23137950 - Lancet Neurol. 2012 Dec;11(12):1017-8 23165336 - Nat Rev Neurol. 2013 Jan;9(1):4 |
| References_xml | – volume: 13 start-page: 190 year: 2010 end-page: 196 ident: bib31 article-title: Amyloid beta from axons and dendrites reduces local spine number and plasticity publication-title: Nat Neurosci – volume: 71 start-page: 85 year: 2008 end-page: 92 ident: bib9 article-title: Biochemical markers in persons with preclinical familial Alzheimer disease publication-title: Neurology – volume: 367 start-page: 795 year: 2012 end-page: 804 ident: bib11 article-title: Clinical and biomarker changes in dominantly inherited Alzheimer's disease publication-title: N Engl J Med – volume: 14 start-page: 298 year: 2001 end-page: 309 ident: bib35 article-title: In vivo mapping of gray matter loss with voxel-based morphometry in mild Alzheimer's disease publication-title: Neuroimage – volume: 31 start-page: 2261 year: 2012 end-page: 2274 ident: bib10 article-title: The mechanism of gamma-secretase dysfunction in familial Alzheimer disease publication-title: EMBO J – volume: 10 start-page: 213 year: 2011 end-page: 220 ident: bib13 article-title: Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer's disease: a retrospective cohort study publication-title: Lancet Neurol – volume: 7 start-page: S220 year: 2011 ident: bib15 article-title: Cortical signature of Alzheimer's disease-related thinning in presymptomatic presenilin-1 mutation carriers publication-title: Alzheimers Dement – volume: 33 start-page: 1 year: 2012 end-page: 5 ident: bib24 article-title: Cerebrospinal fluid biomarkers and proximity to diagnosis in preclinical familial Alzheimer's disease publication-title: Dement Geriatr Cogn Disord – volume: 59 start-page: 512 year: 2006 end-page: 519 ident: bib26 article-title: Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Ab42 in humans publication-title: Ann Neurol – volume: 32 start-page: 1765 year: 2011 end-page: 1773 ident: bib17 article-title: Acceleration of cortical thinning in familial Alzheimer's disease publication-title: Neurobiol Aging – volume: 277 start-page: 793 year: 1997 end-page: 799 ident: bib12 article-title: Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation publication-title: JAMA – volume: 64 start-page: 343 year: 2007 end-page: 349 ident: bib23 article-title: Cerebrospinal fluid tau/b-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults publication-title: Arch Neurol – volume: 6 start-page: 494 year: 2007 end-page: 500 ident: bib7 article-title: Cortical morphology in children and adolescents with different apolipoprotein E gene polymorphisms: an observational study publication-title: Lancet Neurol – volume: 47 start-page: 1778 year: 2006 end-page: 1786 ident: bib34 article-title: Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease publication-title: J Nucl Med – volume: 22 start-page: 307 year: 2010 end-page: 313 ident: bib6 article-title: Reduced posterior cingulate mitochondrial activity in expired young adult carriers of the APOE epsilon4 allele, the major late-onset Alzheimer's susceptibility gene publication-title: J Alzheimers Dis – volume: 14 start-page: 750 year: 2011 end-page: 756 ident: bib32 article-title: Neuronal activity regulates the regional vulnerability to amyloid-beta deposition publication-title: Nat Neurosci – volume: 297 start-page: 353 year: 2002 end-page: 356 ident: bib1 article-title: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics publication-title: Science – volume: 106 start-page: 7209 year: 2009 end-page: 7214 ident: bib3 article-title: Distinct patterns of brain activity in young carriers of the APOE-epsilon4 allele publication-title: Proc Natl Acad Sci USA – volume: 45 start-page: 655 year: 2007 end-page: 660 ident: bib20 article-title: Validity and reliability of the CERAD-Col neuropsychological battery publication-title: Rev Neurol – year: 2012 ident: bib27 article-title: Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study publication-title: Lancet Neurol – volume: 26 start-page: 10222 year: 2006 end-page: 10231 ident: bib18 article-title: Alterations in memory networks in mild cognitive impairment and Alzheimer's disease: an independent component analysis publication-title: J Neurosci – volume: 25 start-page: 7709 year: 2005 end-page: 7717 ident: bib30 article-title: Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory publication-title: J Neurosci – volume: 101 start-page: 284 year: 2004 end-page: 289 ident: bib5 article-title: Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia publication-title: Proc Natl Acad Sci USA – volume: 68 start-page: 865 year: 2010 end-page: 875 ident: bib14 article-title: Hippocampal hyperactivation in presymptomatic familial Alzheimer's disease publication-title: Ann Neurol – volume: 334 start-page: 752 year: 1996 end-page: 758 ident: bib28 article-title: Preclinical evidence of Alzheimer's disease in persons homozygous for the e4 allele for apolipoprotein E publication-title: N Engl J Med – volume: 107 start-page: 17763 year: 2010 end-page: 17767 ident: bib29 article-title: Spatial correlation between brain aerobic glycolysis and amyloid-beta (Abeta) deposition publication-title: Proc Natl Acad Sci USA – volume: 9 start-page: 119 year: 2010 end-page: 128 ident: bib2 article-title: Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade publication-title: Lancet Neurol – volume: 19 start-page: 497 year: 2009 end-page: 510 ident: bib19 article-title: The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals publication-title: Cereb Cortex – volume: 15 start-page: 337 year: 2003 end-page: 349 ident: bib21 article-title: Mag M, Giraldo Chica M, Ardila A, Pineda Salazar DA, Lopera Restrepo FJ. Nongenetic factors as modifiers of the age of onset of familial Alzheimer's disease publication-title: Int Psychogeriatr – volume: 48 start-page: 913 year: 2005 end-page: 922 ident: bib33 article-title: Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo publication-title: Neuron – volume: 278 start-page: 7010 year: 2003 end-page: 7018 ident: bib25 article-title: Familial Alzheimer disease-linked presenilin 1 variants enhance production of both Abeta 1-40 and Abeta 1-42 peptides that are only partially sensitive to a potent aspartyl protease transition state inhibitor of “gamma-secretase” publication-title: J Biol Chem – year: 1988 ident: bib22 publication-title: Co-planar stereotaxic atlas of the human brain – volume: 129 start-page: 2908 year: 2006 end-page: 2922 ident: bib16 article-title: Enhanced brain activity may precede the diagnosis of Alzheimer's disease by 30 years publication-title: Brain – volume: 7 start-page: 280 year: 2011 end-page: 292 ident: bib4 article-title: Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Association workgroup publication-title: Alzheimers Dement – volume: 3 start-page: 1 year: 2011 ident: bib8 article-title: Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease publication-title: Alzheimers Res Ther – volume: 48 start-page: 913 year: 2005 ident: 10.1016/S1474-4422(12)70228-4_bib33 article-title: Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo publication-title: Neuron doi: 10.1016/j.neuron.2005.10.028 – volume: 367 start-page: 795 year: 2012 ident: 10.1016/S1474-4422(12)70228-4_bib11 article-title: Clinical and biomarker changes in dominantly inherited Alzheimer's disease publication-title: N Engl J Med doi: 10.1056/NEJMoa1202753 – volume: 64 start-page: 343 year: 2007 ident: 10.1016/S1474-4422(12)70228-4_bib23 article-title: Cerebrospinal fluid tau/b-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults publication-title: Arch Neurol doi: 10.1001/archneur.64.3.noc60123 – volume: 13 start-page: 190 year: 2010 ident: 10.1016/S1474-4422(12)70228-4_bib31 article-title: Amyloid beta from axons and dendrites reduces local spine number and plasticity publication-title: Nat Neurosci doi: 10.1038/nn.2476 – volume: 9 start-page: 119 year: 2010 ident: 10.1016/S1474-4422(12)70228-4_bib2 article-title: Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade publication-title: Lancet Neurol doi: 10.1016/S1474-4422(09)70299-6 – volume: 14 start-page: 298 year: 2001 ident: 10.1016/S1474-4422(12)70228-4_bib35 article-title: In vivo mapping of gray matter loss with voxel-based morphometry in mild Alzheimer's disease publication-title: Neuroimage doi: 10.1006/nimg.2001.0848 – volume: 31 start-page: 2261 year: 2012 ident: 10.1016/S1474-4422(12)70228-4_bib10 article-title: The mechanism of gamma-secretase dysfunction in familial Alzheimer disease publication-title: EMBO J doi: 10.1038/emboj.2012.79 – volume: 6 start-page: 494 year: 2007 ident: 10.1016/S1474-4422(12)70228-4_bib7 article-title: Cortical morphology in children and adolescents with different apolipoprotein E gene polymorphisms: an observational study publication-title: Lancet Neurol doi: 10.1016/S1474-4422(07)70106-0 – volume: 278 start-page: 7010 year: 2003 ident: 10.1016/S1474-4422(12)70228-4_bib25 article-title: Familial Alzheimer disease-linked presenilin 1 variants enhance production of both Abeta 1-40 and Abeta 1-42 peptides that are only partially sensitive to a potent aspartyl protease transition state inhibitor of “gamma-secretase” publication-title: J Biol Chem doi: 10.1074/jbc.M209252200 – year: 2012 ident: 10.1016/S1474-4422(12)70228-4_bib27 article-title: Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study publication-title: Lancet Neurol doi: 10.1016/S1474-4422(12)70227-2 – volume: 7 start-page: S220 year: 2011 ident: 10.1016/S1474-4422(12)70228-4_bib15 article-title: Cortical signature of Alzheimer's disease-related thinning in presymptomatic presenilin-1 mutation carriers publication-title: Alzheimers Dement doi: 10.1016/j.jalz.2011.05.618 – volume: 68 start-page: 865 year: 2010 ident: 10.1016/S1474-4422(12)70228-4_bib14 article-title: Hippocampal hyperactivation in presymptomatic familial Alzheimer's disease publication-title: Ann Neurol doi: 10.1002/ana.22105 – volume: 14 start-page: 750 year: 2011 ident: 10.1016/S1474-4422(12)70228-4_bib32 article-title: Neuronal activity regulates the regional vulnerability to amyloid-beta deposition publication-title: Nat Neurosci doi: 10.1038/nn.2801 – volume: 106 start-page: 7209 year: 2009 ident: 10.1016/S1474-4422(12)70228-4_bib3 article-title: Distinct patterns of brain activity in young carriers of the APOE-epsilon4 allele publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0811879106 – volume: 15 start-page: 337 year: 2003 ident: 10.1016/S1474-4422(12)70228-4_bib21 article-title: Mag M, Giraldo Chica M, Ardila A, Pineda Salazar DA, Lopera Restrepo FJ. Nongenetic factors as modifiers of the age of onset of familial Alzheimer's disease publication-title: Int Psychogeriatr doi: 10.1017/S1041610203009591 – volume: 47 start-page: 1778 year: 2006 ident: 10.1016/S1474-4422(12)70228-4_bib34 article-title: Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease publication-title: J Nucl Med – volume: 32 start-page: 1765 year: 2011 ident: 10.1016/S1474-4422(12)70228-4_bib17 article-title: Acceleration of cortical thinning in familial Alzheimer's disease publication-title: Neurobiol Aging doi: 10.1016/j.neurobiolaging.2009.11.013 – volume: 33 start-page: 1 year: 2012 ident: 10.1016/S1474-4422(12)70228-4_bib24 article-title: Cerebrospinal fluid biomarkers and proximity to diagnosis in preclinical familial Alzheimer's disease publication-title: Dement Geriatr Cogn Disord doi: 10.1159/000335729 – volume: 7 start-page: 280 year: 2011 ident: 10.1016/S1474-4422(12)70228-4_bib4 article-title: Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Association workgroup publication-title: Alzheimers Dement doi: 10.1016/j.jalz.2011.03.003 – volume: 107 start-page: 17763 year: 2010 ident: 10.1016/S1474-4422(12)70228-4_bib29 article-title: Spatial correlation between brain aerobic glycolysis and amyloid-beta (Abeta) deposition publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.1010461107 – volume: 3 start-page: 1 year: 2011 ident: 10.1016/S1474-4422(12)70228-4_bib8 article-title: Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease publication-title: Alzheimers Res Ther doi: 10.1186/alzrt59 – volume: 26 start-page: 10222 year: 2006 ident: 10.1016/S1474-4422(12)70228-4_bib18 article-title: Alterations in memory networks in mild cognitive impairment and Alzheimer's disease: an independent component analysis publication-title: J Neurosci doi: 10.1523/JNEUROSCI.2250-06.2006 – volume: 19 start-page: 497 year: 2009 ident: 10.1016/S1474-4422(12)70228-4_bib19 article-title: The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals publication-title: Cereb Cortex doi: 10.1093/cercor/bhn113 – volume: 101 start-page: 284 year: 2004 ident: 10.1016/S1474-4422(12)70228-4_bib5 article-title: Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.2635903100 – volume: 22 start-page: 307 year: 2010 ident: 10.1016/S1474-4422(12)70228-4_bib6 article-title: Reduced posterior cingulate mitochondrial activity in expired young adult carriers of the APOE epsilon4 allele, the major late-onset Alzheimer's susceptibility gene publication-title: J Alzheimers Dis doi: 10.3233/JAD-2010-100129 – volume: 129 start-page: 2908 year: 2006 ident: 10.1016/S1474-4422(12)70228-4_bib16 article-title: Enhanced brain activity may precede the diagnosis of Alzheimer's disease by 30 years publication-title: Brain doi: 10.1093/brain/awl266 – volume: 45 start-page: 655 year: 2007 ident: 10.1016/S1474-4422(12)70228-4_bib20 article-title: Validity and reliability of the CERAD-Col neuropsychological battery publication-title: Rev Neurol doi: 10.33588/rn.4511.2007086 – volume: 25 start-page: 7709 year: 2005 ident: 10.1016/S1474-4422(12)70228-4_bib30 article-title: Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory publication-title: J Neurosci doi: 10.1523/JNEUROSCI.2177-05.2005 – year: 1988 ident: 10.1016/S1474-4422(12)70228-4_bib22 – volume: 334 start-page: 752 year: 1996 ident: 10.1016/S1474-4422(12)70228-4_bib28 article-title: Preclinical evidence of Alzheimer's disease in persons homozygous for the e4 allele for apolipoprotein E publication-title: N Engl J Med doi: 10.1056/NEJM199603213341202 – volume: 71 start-page: 85 year: 2008 ident: 10.1016/S1474-4422(12)70228-4_bib9 article-title: Biochemical markers in persons with preclinical familial Alzheimer disease publication-title: Neurology doi: 10.1212/01.wnl.0000303973.71803.81 – volume: 277 start-page: 793 year: 1997 ident: 10.1016/S1474-4422(12)70228-4_bib12 article-title: Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation publication-title: JAMA doi: 10.1001/jama.1997.03540340027028 – volume: 59 start-page: 512 year: 2006 ident: 10.1016/S1474-4422(12)70228-4_bib26 article-title: Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Ab42 in humans publication-title: Ann Neurol doi: 10.1002/ana.20730 – volume: 10 start-page: 213 year: 2011 ident: 10.1016/S1474-4422(12)70228-4_bib13 article-title: Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer's disease: a retrospective cohort study publication-title: Lancet Neurol doi: 10.1016/S1474-4422(10)70323-9 – volume: 297 start-page: 353 year: 2002 ident: 10.1016/S1474-4422(12)70228-4_bib1 article-title: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics publication-title: Science doi: 10.1126/science.1072994 – reference: 23137950 - Lancet Neurol. 2012 Dec;11(12):1017-8 – reference: 23165336 - Nat Rev Neurol. 2013 Jan;9(1):4 |
| SSID | ssj0021481 |
| Score | 2.5681221 |
| Snippet | We have previously characterised functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's disease. To gain further knowledge... Summary Background We have previously characterised functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's disease. To gain... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1048 |
| SubjectTerms | Adolescent Adult Alzheimer Disease - diagnosis Alzheimer Disease - genetics Alzheimer Disease - metabolism Alzheimer's disease Amyloid beta-Peptides - blood Amyloid beta-Peptides - cerebrospinal fluid Biomarkers Biomarkers - blood Biomarkers - cerebrospinal fluid Brain - pathology Case-Control Studies Cross-Sectional Studies Female Genes, Dominant Genetic Predisposition to Disease - genetics Humans Magnetic Resonance Imaging - methods Male Medical imaging Mutation Mutation - genetics Neuroimaging Neurology Peptide Fragments - blood Peptide Fragments - cerebrospinal fluid Presenilin-1 - blood Presenilin-1 - cerebrospinal fluid Presenilin-1 - genetics Risk Factors Young Adult Young adults |
| Title | Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1474442212702284 https://www.clinicalkey.es/playcontent/1-s2.0-S1474442212702284 https://dx.doi.org/10.1016/S1474-4422(12)70228-4 https://www.ncbi.nlm.nih.gov/pubmed/23137948 https://www.proquest.com/docview/1197648109 https://www.proquest.com/docview/1171873378 https://www.proquest.com/docview/1272727827 |
| Volume | 11 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwELaglRAXxJstpRokJOBgmsRO7HBBW7RVhdQKAZX2ZjmOo67Y7i6b7KH8J_4jM4mTvdCWq-MviTL2-JvMi7E3pZCWHD6cApm4dLnleeQjrq2N8sJapdsCpqdn2cm5_DJNp-GHWx3CKnud2CrqcunoH_khubsyqeMo_7T6xalrFHlXQwuNu2yXSpfRqlbTrcGFVL81uKSSXMok2WbwHH4fBt_FyXtFVWC4vO5suo57tmfQ8UP2IJBHGHfSfsTu-MVjdu80uMefsD9H1PABZpdt6yGwixKq-WZWAiXZUxzOGse6IiSA865op0NbgaMG2wCuJUppBAo3BySzYDfNskbkHMplFzID4_nvCz-79Ou3NQTnDt0KaSSs2kymGfJWiGGS6GgMP2cUL1l-BAsOZ_IQGA9tUdun7Px48uPzCQ_9GLjLdNxwFbnYovL0VapzJ3SROOEFWpA-cTgoRKWUq4oCrd7MlqIq0ZZLy9SikSkiXLHiGdtZLBf-BQOlC2Ut2pZFTjJIizzFWxSikmWcuSoaMdlLwrhQrJx6ZszNEJVGAjQENnFiWgEaOWIfBtiqq9ZxGyDrxWz6VFRUngbPk9uA6l9AXwcVUJvY1ImJOjSBycWPUETqARlYTsde_ueh-_1KNNvnDBtjxF4Pl1FJkOfHLvxyQ3OQgighlL5hTkI-eSSMasSed6t8-IZoBAhU3Hrv5hd4ye4jn0y6aJ99ttOsN_4VcramOGg35gHbPZqcff32F5nOOz4 |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKkYAL4s1CgUECAQfTxHZiBwmhBVpt6eNCK-3NdRJHrNjuLptdofKf4Dcyk9deaMulV8efE2Wc8UzmmxnGXuRSOQr4cCIycZUljieBD7hxLkhS57SpCpjuH8SDI_VlGA3X2J82F4Zola1OrBR1Ps3oH_kmhbtiZcIg-TD7walrFEVX2xYa9bbY9ac_0WUr3-98Rvm-FGJ76_DTgDddBXgWm3DBdZCFDlWALyKTZNKkIpNeoh_kRYaDUhZaZ0Waou8Wu1wWOXokUR45dJVkgO9d4rpX2FU8eANy9vRw5eCha1E5eEorrpQQq4yhza_d4OtQvNFUdYars87Cs2zd6szbvsVuNsYq9OvddZut-ckddm2_CcffZb8_UoMJGJ1UrY7ATXIoxstRDpTUT7yfOY7VRU8A552SZoGq4kcJbgG4dymFEojeDmg8g1supiUix5BPa4oO9Me_vvnRiZ-_KqEJJtFSaLbCrMqcGqGdDCFsCRP04fuI-Jn5O3CQ4UzeEPGhKqJ7jx1diqTus_XJdOIfMtAm1c6hL5smJIMoTSJcIpWFysM4K4IeU60kbNYUR6ceHWPbseBIgJbANhS2EqBVPfa2g83q6iAXAeJWzLZNfUVlbfH8ugio_wX0ZaNyShvaUtigRhOYKAUIRaTpkI1VVVtL_3PTjXYn2tV9ug-xx553l1EpUaTJTfx0SXPQ5NFSanPOHEEcADRQdY89qHd59w7R6ZB4UJhH5z_AM3Z9cLi_Z_d2DnYfsxtoy4qaabTB1hfzpX-C9uIifVp9pMCOL1sr_AXYzHcH |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtNAEF6VVKq4IP4JFBgkEHDYxt5de20khFKaqKU0qoBKvS1rey0i0iTEiVB5J16Ap2PGf73Qlkuvm511lBnPfpP5Zoax55lUlhI-nIhMXKWx5bHnPB5Z68WJtToqG5gejMLdI_XhODheY3-aWhiiVTY-sXTU2Syl_8h7lO4KVeR7cS-vaRGHO8N38x-cJkhRprUZp1GZyL47_YnhW_F2bwd1_UKI4eDL-11eTxjgaRj5S6691LfoDlweRHEqo0Sk0kmMiZxIcVHKXOs0TxKM40KbyTzD6CTIAothk_RQBxLPvcbWNUVFHba-PRgdfmrDPQw0ynBPacWVEuKsfqj3uV185YvXmnrQcHXezXge8i1vwOFNdqOGrtCvbO0WW3PT22zjoE7O32G_t2ncBIxPysFHYKcZ5JPVOAMq8ScW0ALXqhYogPtOyc9A2f-jALsEtGQqqAQiuwNCabCr5axAyQlks4qwA_3Jr29ufOIWLwuoU0t0FIJYmJd1VGNEzeDDQEReH76Pia2ZvQELKe7kNS0fypa6d9nRlejqHutMZ1P3gIGOEm0tRrZJTDoIkjjAIxKZq8wP09zrMtVowqR1q3Sa2DExLSeOFGhI2PjClAo0qsu2WrF51SvkMoGwUbNpCmHRdRu8zS4T1P8SdEXtgArjm0IYr5ImYSIYoChKRq1kjbEq7PQ_D91sLNGcPad9LbvsWfsxuijKO9mpm61oDwIgLaWOLtgjiBGAcFV32f3KytvfEEMQiddG9PDiL_CUbaBHMB_3RvuP2HUEtqKiHW2yznKxco8RPC6TJ_VbCuzrVTuGvym7fKI |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Brain+imaging+and+fluid+biomarker+analysis+in+young+adults+at+genetic+risk+for+autosomal+dominant+Alzheimer%27s+disease+in+the+presenilin+1+E280A+kindred%3A+a+case-control+study&rft.jtitle=Lancet+neurology&rft.au=Reiman%2C+Eric+M&rft.au=Quiroz%2C+Yakeel+T&rft.au=Fleisher%2C+Adam+S&rft.au=Chen%2C+Kewei&rft.date=2012-12-01&rft.issn=1474-4465&rft.eissn=1474-4465&rft.volume=11&rft.issue=12&rft.spage=1048&rft_id=info:doi/10.1016%2FS1474-4422%2812%2970228-4&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F14744422%2FS1474442212X7025X%2Fcov150h.gif |